GCG and type 2 diabetes mellitus: Although these findings suggests that T2D treatment targeting receptors as GLP-1, GIP and glucagon may activate BCAA catabolism, future studies will be required to investigate if and how activated BCAA catabolism helps to improve glycaemic control upon this treatment in individuals with insulin resistance and T2D.